openPR Logo
Press release

Hyperkalemia Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2023-2032), States DelveInsight | AstraZeneca, Relypsa, Inc., Zeria Pharmaceutical, Ardelyx, Vifor Pharma, Inc., Relypsa, Inc., ZS Pharma

01-30-2024 05:12 PM CET | Health & Medicine

Press release from: DelveInsight Business Research

Hyperkalemia Market is Expected to Expand at a Healthy Growth

DelveInsight's "Hyperkalemia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Hyperkalemia, historical and forecasted epidemiology as well as the Hyperkalemia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Hyperkalemia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Hyperkalemia Market Forecast
https://www.delveinsight.com/sample-request/hyperkalemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Hyperkalemia Market Report:
• The Hyperkalemia market size was valued approximately USD 1,198 million in 2021 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
• Within the EU4 and the UK, Germany led in market size for Hyperkalemia, reaching around USD 49 million in 2021. Anticipated growth suggests that Germany is projected to continue expanding its market presence, with estimates indicating it will maintain the highest market share, followed by the United Kingdom, by the year 2032.
• VELTASSA (Patiromer) provides a successful and well-tolerated approach for the extended-term control of hyperkalemia in patients with chronic kidney disease (CKD) and chronic heart failure (HF).
• The developing pipeline for Hyperkalemia is limited, with only PATIROMER (ZG-801) anticipated to be launched in Japan within the forecast period spanning from 2022 to 2032.
• Key Hyperkalemia Companies: AstraZeneca, Relypsa, Inc., Zeria Pharmaceutical, Ardelyx, Vifor Pharma, Inc., Relypsa, Inc., ZS Pharma, Inc., and others
• Key Hyperkalemia Therapies: LOKELMA 5 GM Powder for Oral Suspension, Sodium Zirconium Cyclosilicate (SZC), patiromer, RDX013, Patiromer, Spironolactone, Zirconium silicate (ZS), and others
• The Hyperkalemia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Hyperkalemia pipeline products will significantly revolutionize the Hyperkalemia market dynamics.

Hyperkalemia Overview
Hyperkalemia is a medical condition characterized by elevated levels of potassium in the blood. Potassium is an essential electrolyte that plays a crucial role in various bodily functions, including the proper functioning of muscles, nerves, and the heart. However, when the concentration of potassium in the blood becomes higher than normal, it can lead to health problems.

Get a Free sample for the Hyperkalemia Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/hyperkalemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Hyperkalemia Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Hyperkalemia Epidemiology Segmentation:
The Hyperkalemia market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of Hyperkalemia
• Prevalent Cases of Hyperkalemia by severity
• Gender-specific Prevalence of Hyperkalemia
• Diagnosed Cases of Episodic and Chronic Hyperkalemia

Download the report to understand which factors are driving Hyperkalemia epidemiology trends @ Hyperkalemia Epidemiology Forecast
https://www.delveinsight.com/sample-request/hyperkalemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Hyperkalemia Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hyperkalemia market or expected to get launched during the study period. The analysis covers Hyperkalemia market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Hyperkalemia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Hyperkalemia Therapies and Key Companies
• LOKELMA 5 GM Powder for Oral Suspension: AstraZeneca
• Sodium Zirconium Cyclosilicate (SZC): AstraZeneca
• patiromer: Relypsa, Inc.
• patiromer: Zeria Pharmaceutical
• RDX013: Ardelyx
• Patiromer: Vifor Pharma, Inc.
• Spironolactone: Relypsa, Inc.
• Zirconium silicate (ZS): ZS Pharma, Inc.

Discover more about therapies set to grab major Hyperkalemia market share @ Hyperkalemia Treatment Landscape
https://www.delveinsight.com/sample-request/hyperkalemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Scope of the Hyperkalemia Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Hyperkalemia Companies: AstraZeneca, Relypsa, Inc., Zeria Pharmaceutical, Ardelyx, Vifor Pharma, Inc., Relypsa, Inc., ZS Pharma, Inc., and others
• Key Hyperkalemia Therapies: LOKELMA 5 GM Powder for Oral Suspension, Sodium Zirconium Cyclosilicate (SZC), patiromer, RDX013, Patiromer, Spironolactone, Zirconium silicate (ZS), and others
• Hyperkalemia Therapeutic Assessment: Hyperkalemia current marketed and Hyperkalemia emerging therapies
• Hyperkalemia Market Dynamics: Hyperkalemia market drivers and Hyperkalemia market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Hyperkalemia Unmet Needs, KOL's views, Analyst's views, Hyperkalemia Market Access and Reimbursement

To know more about Hyperkalemia companies working in the treatment market, visit @ Hyperkalemia Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/hyperkalemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Hyperkalemia Market Report Introduction
2. Executive Summary for Hyperkalemia
3. SWOT analysis of Hyperkalemia
4. Hyperkalemia Patient Share (%) Overview at a Glance
5. Hyperkalemia Market Overview at a Glance
6. Hyperkalemia Disease Background and Overview
7. Hyperkalemia Epidemiology and Patient Population
8. Country-Specific Patient Population of Hyperkalemia
9. Hyperkalemia Current Treatment and Medical Practices
10. Hyperkalemia Unmet Needs
11. Hyperkalemia Emerging Therapies
12. Hyperkalemia Market Outlook
13. Country-Wise Hyperkalemia Market Analysis (2019-2032)
14. Hyperkalemia Market Access and Reimbursement of Therapies
15. Hyperkalemia Market Drivers
16. Hyperkalemia Market Barriers
17. Hyperkalemia Appendix
18. Hyperkalemia Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Reports:
Hyperkalemia Pipeline https://www.delveinsight.com/report-store/hyperkalemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"Hyperkalemia Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Hyperkalemia market. A detailed picture of the Hyperkalemia pipeline landscape is provided, which includes the disease overview and Hyperkalemia treatment guidelines.
Hyperkalemia Epidemiology https://www.delveinsight.com/report-store/hyperkalemia-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Hyperkalemia Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Hyperkalemia epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports by DelveInsight
Telemedicine Service Market https://www.delveinsight.com/report-store/telemedicine-service-market
Telemedicine Service Market By Service Type (Tele Consulting And Tele Monitoring), By Application (Telepathology, Telecardiology, Teleradiology, Teledermatology, Telepsychiatry, Other Services), By End-User (Healthcare Facilities And Homecare), by geography, is projected to grow at a significant CAGR forecast till 2028 owing to the sudden outbreak of covid-19 pandemic and shifting focus for reducing the burden of healthcare cost

Wearable Medical Devices Market https://www.delveinsight.com/report-store/wearable-medical-devices-market
Wearable Medical Devices Market By Device Type (Diagnostic And Monitoring Devices [Vital Sign Monitoring Devices, Sleep Monitoring Devices, Electrocardiographs Fetal And Obstetric Devices, Neuromonitoring Devices, And Others] And Therapeutic Devices [Pain Management Devices, Rehabilitation Devices, Respiratory Therapy Devices, And Others]), By Product Type (Wristband, Headband, Ear Wear, Watch, And Others), By Application (Sports And Fitness, Remote Patient Monitoring, And Home Healthcare), By Distribution Channel (Online And Offline), and by geography is expected to grow at a steady CAGR forecast till 2028 owing to a rise in the geriatric population and increasing prevalence of chronic diseases across the globe.

Surgical Robotic System Market https://www.delveinsight.com/report-store/surgical-robotic-system-market
Surgical Robotic Systems Market By Application (Urology, Gynecology, Neurosurgery, Orthopedics, And Others), By End User (Hospitals, Ambulatory Surgical Centers, And Others), And by geography is estimated to register appreciable CAGR forecast till 2028 owing to increase in surgical procedures and rising popularity of minimally invasive surgical interventions.

Cancer Diagnostics Market
https://www.delveinsight.com/report-store/cancer-diagnostic-market
Cancer Diagnostics Market By Type (Product Type [Reagent & Kits and Instruments], and Services), Technique (Molecular Diagnostics [Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Fluorescent In-Situ Hybridization (FISH), Microarray, and Immunohistochemistry], Diagnostics Imaging [Ultrasound & Radiology, Mammography, MRI Scan, CT Scan, and Nuclear Medicine Scans], Endoscopy, and Biopsy [Standard Biopsy and Liquid Biopsy]), Cancer Type (Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer, and Others), End-User (Hospitals, Diagnostics Labs, and Others), and Geography, is expected to grow at a significant CAGR forecast till 2028 owing to the growing burden of cancer across the globe and rise in various product launches for efficient detection of cancer.

Ventilator Market
https://www.delveinsight.com/report-store/ventilators-market
Ventilators Market By Mobility (Intensive Care Ventilators, Portable/Transportable Ventilators), By Type (Adult/Pediatric Ventilators, Neonatal/Infant Ventilators), By Interface (Invasive Ventilation, Non-Invasive Ventilation), By End-User (Hospitals, Home Care, Ambulatory Surgical Centers, Others), By Geography is expected to grow at a steady CAGR forecast till 2028 owing to lauch of advanced devices and increasing prevalence of respiratory diseases such as COPD.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Contact No.: +91-9650213330
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Hyperkalemia Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2023-2032), States DelveInsight | AstraZeneca, Relypsa, Inc., Zeria Pharmaceutical, Ardelyx, Vifor Pharma, Inc., Relypsa, Inc., ZS Pharma here

News-ID: 3366594 • Views:

More Releases from DelveInsight Business Research

Gastric Cancer Market to Exceed USD 700 Million in HER2+ Segment by 2034 Across 7MM, Backed by 211,550 Annual Cases and 15+ Key Therapies | DelveInsight
Gastric Cancer Market to Exceed USD 700 Million in HER2+ Segment by 2034 Across …
Gastric cancer is the fifth most common malignancy worldwide, with incidence varying by region and highest rates reported in Eastern Asia and Eastern Europe. Japan records the highest burden among the 7MM, with about 129,500 cases in 2024. Many patients, particularly in Western countries, are diagnosed at advanced (Stage IV) stages, while Japan detects more cases early (Stage I). In the US, around 35% present with metastatic disease at diagnosis,
Myelofibrosis Market to Double by 2034, Surpassing USD 5.6 Billion Across 7MM with 9% CAGR Growth, states DelveInsight
Myelofibrosis Market to Double by 2034, Surpassing USD 5.6 Billion Across 7MM wi …
The Myelofibrosis market across the seven major markets (7MM) is anticipated to experience significant growth, rising from approximately USD 2,602 million in 2025 to nearly USD 5,638 million by 2034, reflecting a compound annual growth rate (CAGR) of about 9% during the forecast period. In 2024, the market was valued at around USD 2.2 billion, with the United States leading at nearly USD 1.7 billion, far surpassing the EU4, the United
Triple-Negative Breast Cancer Clinical Trial Landscape Expands With 170+ Pipeline Assets, According to DelveInsight
Triple-Negative Breast Cancer Clinical Trial Landscape Expands With 170+ Pipelin …
An expanding portfolio of novel therapies for triple-negative breast cancer (TNBC) including TECENTRIQ (Hoffmann-La Roche), IPI-549 (Infinity Pharmaceuticals), Leronlimab (CytoDyn), MDNA11 (Medicenna Therapeutics), VIP236 (Vincerx Pharma), and CFI-400945 (Treadwell Therapeutics) is anticipated to significantly influence market expansion and transform the TNBC treatment landscape. DelveInsight's Triple Negative Breast Cancer Pipeline Insight report offers an extensive evaluation of more than 165 companies and over 170 therapeutic candidates advancing through the TNBC pipeline. The
Asthma Market to Witness Steady Growth Through 2034 Driven by Novel Biologics and Triple-Combination Therapies | DelveInsight
Asthma Market to Witness Steady Growth Through 2034 Driven by Novel Biologics an …
DelveInsight's latest Asthma Market Insights, Epidemiology, and Market Forecast - 2034 report provides an in-depth evaluation of current treatment practices, emerging asthma drugs, market share of individual therapies, and forecasted market trends across the seven major markets (7MM) - the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The asthma market is expected to experience sustained growth over the next decade, supported by the launch of

All 5 Releases


More Releases for Hyperkalemia

Hyperkalemia Market to Reach USD 4.87 Billion by 2034
Pune, India - December 2025 - The global Hyperkalemia Market, valued at USD 2.87 billion in 2024, is projected to reach USD 4.87 billion by 2034, growing at a 5.4% CAGR (2025-2034), according to Exactitude Consultancy. Increasing cases of chronic kidney disease (CKD), diabetes, heart failure, and widespread use of renin-angiotensin-aldosterone system (RAAS) inhibitors are fuelling the rise in hyperkalemia incidence globally. Download Full PDF Sample Copy of Market Report @
Hyperkalemia Market in Japan to Reach USD 412.7 Million by 2034
Tokyo, Japan - December 2025 - The Japan Hyperkalemia Market, valued at USD 233.5 million in 2024, is projected to reach USD 412.7 million by 2034, growing at a 5.9% CAGR (2025-2034), according to Exactitude Consultancy. The rising prevalence of chronic kidney disease (CKD), heart failure, diabetes, and patients on renin-angiotensin-aldosterone system (RAAS) inhibitors is significantly increasing hyperkalemia burden across Japan. Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71975 Market
Hyperkalemia Japan Market to Reach USD 1.37 Billion by 2034
Hyperkalemia-a condition characterized by elevated potassium levels in the blood-represents a critical challenge in Japan's healthcare landscape. With the nation's rapidly aging population and rising incidence of chronic kidney disease (CKD), heart failure, and diabetes, effective management of hyperkalemia is becoming increasingly vital. Left untreated, hyperkalemia can lead to life-threatening cardiac arrhythmias, making timely diagnosis and treatment essential. Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71975 According to Exactitude Consultancy,
Global Hyperkalemia Treatment Market Research Report 2023
Hyperkalemia Treatment Market Size The global Hyperkalemia Treatment market was valued at US$ 540 million in 2022 and is anticipated to reach US$ 2068.8 million by 2029, witnessing a CAGR of 20.9% during the forecast period 2023-2029. Hyperkalemia Treatment Market Hyperkalemia is a diseases in which levels of potassium are higher than normal level (3.5 and 5.0 mmol/L) in blood serum. Kidneys are responsible for managing potassium balance in the body by regulating
Hyperkalemia Treatment Market Size, Share, Industry, Forecast to 2030
The Hyperkalemia Treatment Market 2023 Report makes available the current and forthcoming technical and financial details of the industry. It is one of the most comprehensive and important additions to the Prudent Markets archive of market research studies. It offers detailed research and analysis of key aspects of the global Hyperkalemia Treatment market. This report explores all the key factors affecting the growth of the global Hyperkalemia Treatment market, including
Global Hyperkalemia Supplement Market, Size, Share, Analysis Report & Forecast t …
The global hyperkalemia treatment market is anticipated to grow at a significant CAGR during the forecast period. The major factor for the growth of the market is the increasing chronic diseases such as acute hyperkalemia and chronic hyperkalemia due to other ailments such as diabetes, consumption of high potassium diets, and many other things. As per the National Kidney Foundation, more than 37 million people in the United States have